Group 1 - Dongyangguang plans to acquire control of Dongshu Yihua, which was established for the acquisition of Qinhuai Data [1] - Kaipu Cloud terminates the acquisition of 100% equity in Nanning Taike [1] - YN Energy Holdings only holds a stake in Xiantian Computing and does not consolidate financial statements; its main business remains thermal power generation [1] - Jiaze New Energy's green chemical business is still in the early stages and has not yet been commercialized [1] Group 2 - Tongwei Co. plans to issue shares and cash to acquire 100% equity in Qinghai Lihua Qingneng and has suspended trading to plan the transaction [2] - Hengrui Medicine's SHR-1918 injection application has been accepted by the National Medical Products Administration and included in priority review [2] - ST Renfu plans to raise no more than 3.5 billion yuan through a private placement to its controlling shareholder [2] - Changxin Bochuang intends to acquire 93.81% equity in Shanghai Honghui Guanglian Communication Technology Co., expanding into the upstream of the optical communication industry chain [2] - Bohai Leasing's subsidiary sells 24 aircraft leasing assets with a market price of approximately 1.589 billion USD [2] - Shenlian Bio plans to acquire control of Shizhi Yuan for 237 million yuan and develop innovative drug business [2] - Sainuo Medical's subsidiary product Ghunter intracranial thrombectomy stent has obtained EU CE MDR certification [2] - Dazhu Laser plans to invest 150 million USD to establish an overseas operation center in Southeast Asia [2] - ST Songfa's subsidiary Henglizhaobing has signed contracts for the construction of two Capesize bulk carriers [2] - Shaaneng Co.'s wholly-owned subsidiary has signed a cooperation agreement for land and power resources for an independent energy storage project with Yuancan Company [2] - Guangxi Media's film "Fast Life 3" has a cumulative box office of 2.926 billion yuan, generating revenue of 43-53 million yuan; "Silent Insect" has a box office of 867 million yuan, generating revenue of 5.2-6.6 million yuan [2] - Xingfu Blue Sea's revenue from two films "Fast Life 3" and "Bears: Year of the Bear" totals approximately 790,000-1.02 million yuan [2] - Huazhi Digital Media's film "Silent Insect" has a cumulative box office exceeding 900 million yuan, accounting for over 50% of the recent year's revenue [2] - Xiangyuan Cultural Tourism received 1.1428 million visitors during the 2026 Spring Festival, achieving revenue of 70.9237 million yuan [2] - Sanan Optoelectronics plans to dispose of equipment that does not meet demand, with a book value of 447 million yuan [2] Group 3 - Sangfor Technologies expects a net profit growth of 317.09% in 2025 [3] - Yongxi Electronics anticipates a net profit of 82.24 million yuan in 2025, a year-on-year increase of 23.99% [3] - Zhongke Shuguang forecasts a net profit of 2.113 billion yuan in 2025, a year-on-year growth of 11% [3]

Core Viewpoint - The company, Sainuo Medical Technology Co., Ltd., has successfully obtained the EU CE MDR certification for its Ghunter intracranial thrombectomy stent, marking its first overseas registration certification for a self-developed product [1][3]. Group 1: Product Registration and Certification - The Ghunter intracranial thrombectomy stent has been registered with the EU announcement agency under the EU Medical Devices Regulation (EU) 2017/745 [1]. - The product received the EU CE MDR certification, which includes the EU Quality Management System Certificate and the EU Technical Documentation Assessment Certificate [1][3]. - The certification was issued on February 18, 2026, and is valid until February 1, 2031 [3]. Group 2: Product Specifications and Usage - The Ghunter stent is designed for the removal of thrombus in large intracranial vessels of ischemic stroke patients within 24 hours of symptom onset [2]. - The stent features a full visualization design, curled design for better wall adherence, and various mesh sizes to enhance thrombus capture capabilities [3]. Group 3: Impact on the Company - The certification signifies that Sainuo Shenchang has established a quality management system compliant with EU MDR requirements, allowing the stent to meet the latest market entry conditions in the EU [3]. - This approval is expected to positively influence the promotion and sales of the company's products in relevant markets, enhancing market competitiveness and future business operations [3].

Core Viewpoint - The announcement highlights that Sino Medical Technology Co., Ltd.'s subsidiary, Sino Shenchang Medical Technology Co., Ltd., has received EU CE MDR certification for its Ghunter intracranial thrombectomy stent, marking a significant milestone for the company in entering the European market [2][5]. Group 1: Certification Details - The Ghunter intracranial thrombectomy stent was registered under the EU Medical Devices Regulation (EU) 2017/745 and has received the EU CE MDR certification [2]. - The product is designed for the removal of thrombus in large vessels of ischemic stroke patients within 24 hours of symptom onset, and it is a single-use device with a shelf life of 2 years [3][4]. - The certification includes an EU Quality Management System Certificate and an EU Technical Documentation Assessment Certificate, with the certificate issued on February 18, 2026, and expiring on February 1, 2031 [4]. Group 2: Product Features - The Ghunter stent features a full visualization design for improved surgical visibility, a curled design for better wall adherence and thrombosis capture, and various mesh sizes to enhance its ability to capture different types of thrombus [4]. - The product has already received a medical device registration certificate from the National Medical Products Administration of China in April 2023 [4]. Group 3: Impact on the Company - The certification signifies that Sino Shenchang has established a quality management system compliant with EU MDR requirements, allowing the stent to meet the latest market entry conditions in the EU [5]. - This approval is expected to positively impact the promotion and sales of the company's products in relevant markets, enhancing the company's market competitiveness and future operations [5].

Group 1: Key Developments in Technology and Innovation - Elon Musk envisions launching AI satellites from the Moon using electromagnetic catapults to create a satellite network for data centers [4] - Xiaomi plans to focus on core technologies such as chips, AI, and operating systems over the next five years to become a global tech leader [3] - Apple intends to purchase over 100 million advanced chips from TSMC's Arizona factory by 2026 [5] Group 2: Investment and Financial Performance - Hubei province is increasing investments in emerging industries like integrated circuits and embodied intelligence while optimizing real estate investments to boost domestic demand [2] - AMD has agreed to sell AI chips worth up to $60 billion to Meta, which will deploy 6 GW of AMD GPUs [6] - Zhongwei Semiconductor reported a net profit of 285 million yuan for 2025, a year-on-year increase of 108.05% [9] - Sry New Materials achieved a net profit of 154 million yuan in 2025, reflecting a 35.04% year-on-year growth [12] - Sanofi Guojian reported a net profit of 2.939 billion yuan for 2025, a staggering increase of 317.09% [12] Group 3: Corporate Actions and Strategic Moves - Shenlian Bio plans to acquire a controlling stake in Shizhi Yuan for 237 million yuan to expand into innovative pharmaceuticals [8] - Kaipu Cloud terminated its acquisition of Nanning Taike due to market changes and lack of agreement on key terms [8] - Senno Medical's subsidiary received EU CE MDR certification for its Ghunter intracranial thrombectomy stent, enabling entry into the EU market [14] Group 4: Financing and Market Activity - Qianxun Intelligent completed nearly 2 billion yuan in financing, with a valuation exceeding 10 billion yuan [15] - Renxin Technology, a leader in high-speed automotive SerDes chips, completed a strategic round of financing led by SAIC and other industry capital [16]

Core Viewpoint - Sino Medical (688108.SH) announced that its subsidiary, Sino Shenchang Medical Technology Co., Ltd., has submitted registration materials for the Ghunter intracranial thrombectomy stent to the EU Notified Body under the Medical Devices Regulation (EU) 2017/745, and has received CE MDR certification, marking the first overseas registration for a self-developed product [1] Group 1 - The Ghunter intracranial thrombectomy stent has obtained CE MDR certification according to EU regulations [1] - This certification indicates that Sino Shenchang has established a quality management system compliant with EU MDR requirements [1] - The product can now be sold in regions that recognize EU medical device regulations, enhancing its market competitiveness [1] Group 2 - The approval is expected to positively impact the promotion and sales of the company's products in the relevant markets [1] - This development will contribute to the company's future operations and overall business performance [1]

Core Viewpoint - The company has successfully obtained EU CE MDR certification for its Ghunter intracranial thrombectomy stent, marking its first overseas registration for a self-developed product, which enhances its market competitiveness and operational prospects [1][2]. Group 1: Product Development and Certification - The Ghunter intracranial thrombectomy stent is a self-developed acute ischemic product by the company's subsidiary, featuring full visibility design, curled design for better wall adherence, and various mesh sizes to improve thrombosis engagement [1]. - The product received the Medical Device Registration Certificate from the National Medical Products Administration of China in April 2023 and subsequently obtained EU CE MDR certification in February 2026 [1]. Group 2: Market Impact and Quality Management - The approval signifies that the subsidiary has established a quality management system compliant with EU MDR regulations, allowing the stent to meet the latest market entry conditions in the EU and other regions recognizing EU medical device regulations [2]. - This certification is expected to positively impact the promotion and sales of the company's products in relevant markets, thereby enhancing the company's market competitiveness and future business operations [2].

Core Viewpoint - The announcement indicates that the subsidiary of the company, Sainuo Shenchang, has received CE MDR certification for its Ghunter intracranial thrombectomy stent, which is a significant milestone for market entry in the EU [1] Group 1: Product Development and Certification - The Ghunter stent was granted a medical device registration certificate by the National Medical Products Administration of China in April 2023 [1] - The certification from the EU is valid from February 18, 2026, to February 1, 2031, indicating a long-term approval for the product [1] - The product is designed for acute ischemic conditions and features advantages such as full imaging design and curling design [1] Group 2: Market Impact and Future Considerations - The CE certification allows the product to meet the conditions for market entry in the EU, which is expected to positively influence product promotion and sales, as well as enhance the company's competitiveness [1] - However, further local registration is required, and sales will be influenced by various factors, making the specific impact on performance unpredictable [1]

Core Viewpoint - SINO Medical (688108.SH) announced that its subsidiary, SINO Shenchang, has received EU CE MDR certification for the Ghunter intracranial thrombectomy stent, which is designed for the removal of thrombus in large intracranial vessels of patients with ischemic stroke [1] Group 1 - The Ghunter stent is an acute ischemic product developed independently by SINO Shenchang [1] - The certification indicates that SINO Shenchang has established a management system compliant with EU MDR regulations [1] - The stent meets the latest entry requirements for the EU medical device market [1]